COVID 19

Following the recommendations of the authorities for the coronavirus pandemic, SARA Pharm has taken the necessary measures to ensure the continuity of its activity. The current projects are on-going. The laboratory is operational and the necessary precautions have been taken to allow the safe reception of samples. We do not foresee any impact on our activity to date. In the event of an evolution, we will not fail to keep you informed.

January 21st, 2015

In collaboration with University “Politehnica” Bucharest, Sara Pharm Solution scientists have implemented a knowledge-based, hydrogen bonding propensity model in order to quantify the hydrogen bonding strength between a cytostatic drug and inorganic or inorganic-organic drug delivery systems. Beside fundamental insight into the drug-counterion-carrier system, their efforts have yielded a new strategy for greatly improving the dissolution rate of poorly soluble drugs. More about this topic is available in the RSC Advances paper, found athttp://pubs.rsc.org/en/Content/ArticleLanding/2015/RA/c4ra11224e# .